Tanvex BioPharma, Inc. (TPE:6541)

Tanvex BioPharma Ratios and Metrics

Market cap in millions TWD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jan 12, 2026	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	13,506	10,697	8,715	12,377	20,476	9,894
Market Cap Growth	30.45%	22.75%	-29.59%	-39.55%	106.96%	-9.41%
Enterprise Value	13,659	11,603	9,691	13,133	19,692	9,494
Last Close Price	51.00	64.66	63.95	101.30	167.69	106.94
PS Ratio	60.07	308.48	141.91	552.43	3787.62	32979.06
PB Ratio	2.25	11.98	10.61	8.90	7.33	3.78
P/TBV Ratio	5.05	12.07	10.66	8.97	7.35	3.79
EV/Sales Ratio	60.75	334.59	157.80	586.21	3642.61	31645.92
Debt / Equity Ratio	0.26	1.85	2.11	1.32	0.63	0.58
Asset Turnover	0.04	0.01	0.02	0.01	0.00	0
Inventory Turnover	1.55	0.16	0.01	0.32	0.03	0.00
Quick Ratio	2.32	1.17	1.15	2.68	9.06	5.93
Current Ratio	2.97	1.94	1.66	3.44	9.66	6.41
Return on Equity (ROE)	-37.98%	-161.17%	-193.18%	-78.41%	-56.99%	-74.47%
Return on Assets (ROA)	-14.46%	-30.84%	-42.47%	-24.68%	-22.00%	-33.03%
Return on Capital (ROIC)	-15.61%	-33.29%	-45.40%	-25.78%	-22.99%	-34.93%
Return on Capital Employed (ROCE)	-17.30%	-56.80%	-87.50%	-51.50%	-35.80%	-52.20%
Earnings Yield	-10.05%	-12.91%	-24.52%	-13.26%	-7.54%	-21.27%
FCF Yield	-10.03%	-11.75%	-17.29%	-11.53%	-6.92%	-18.74%
Buyback Yield / Dilution	-48.73%	-20.44%	-9.60%	-8.31%	-21.32%	-9.25%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.